US FDA’s Opaque Galafold Review: A Rare Misstep In The Trump Era
Executive Summary
When FDA reversed course and allowed Amicus to file for Accelerated Approval of migalastat, plenty of people suspected politics were at play. The agency's handling of the review won’t do anything to allay those suspicions.
You may also be interested in...
Teva Launches First-Ever CREATES Act Suit
Amicus should to be forced to sell samples of Galafold (migalastat) for bioequivalence and other testing, Teva argues in what appears to be the initial case brought under the 2019 law intended to smooth the development of ANDAs.
Teva, In First-Ever CREATES Act Suit, Seeks Help With Fabry Disease Generic Development
Amicus should to be forced to sell samples of Galafold (migalastat) for bioequivalence and other testing, Teva argues in what appears to be the initial case brought under the 2019 law intended to smooth the development of ANDAs.
Will A US FDA Advisory Committee Be In Intercept's Future?
There are strong reasons to justify an advisory committee meeting for the NASH application, but also an outlet for the US FDA to skip it.